<div id="readability-page-1"><p>Cabaletta Bio (NASDAQ:CABA - Get Free Report) is projected to release its  Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Cabaletta Bio to post earnings of ($0.4579) per share for the quarter. Interested persons may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 27, 2026 at 8:00 AM ET.</p><div><p><span></span><span>Get <strong>Cabaletta Bio</strong> alerts:</span></p></div><h2>Cabaletta Bio Stock Up 5.5%</h2><p>NASDAQ CABA opened at $3.43 on Thursday. The stock has a market cap of $330.17 million, a PE ratio of -1.36 and a beta of 3.25. Cabaletta Bio has a fifty-two week low of $0.99 and a fifty-two week high of $3.78. The business has a 50 day moving average price of $2.62 and a two-hundred day moving average price of $2.39. </p><h2>Insider Buying and Selling</h2><p>In related news, insider Steve Gavel acquired 22,170 shares of the business's stock in a transaction that occurred on Wednesday, January 21st. The shares were acquired at an average cost of $2.27 per share, with a total value of $50,325.90. Following the purchase, the insider owned 22,170 shares of the company's stock, valued at approximately $50,325.90. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Nichtberger bought 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was bought at an average price of $2.24 per share, with a total value of $100,800.00. Following the completion of the acquisition, the chief executive officer owned 1,031,483 shares in the company, valued at approximately $2,310,521.92. The trade was a 4.56% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 127,668 shares of company stock valued at $286,211 in the last three months. 11.25% of the stock is currently owned by corporate insiders. </p><h2>Institutional Trading of Cabaletta Bio</h2><p>Hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. lifted its position in  Cabaletta Bio by 17.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company's stock worth $21,590,000 after purchasing an additional 1,495,768 shares during the period.  Adage Capital Partners GP L.L.C. raised its stake in shares of  Cabaletta Bio by 142.9% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company's stock valued at $13,421,000 after buying an additional 5,195,285 shares in the last quarter.  Vanguard Group Inc. lifted its holdings in shares of  Cabaletta Bio by 21.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,190,759 shares of the company's stock worth $9,806,000 after acquiring an additional 740,032 shares during the period.  Millennium Management LLC boosted its position in shares of  Cabaletta Bio by 298.5% during the 4th quarter. Millennium Management LLC now owns 2,736,912 shares of the company's stock valued at $5,994,000 after acquiring an additional 2,050,099 shares in the last quarter.  Finally, Superstring Capital Management LP boosted its position in shares of  Cabaletta Bio by 45.9% during the 4th quarter. Superstring Capital Management LP now owns 2,253,550 shares of the company's stock valued at $4,935,000 after acquiring an additional 709,025 shares in the last quarter. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Separately, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Cabaletta Bio in a research report on Wednesday, January 21st. Seven research analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to data from MarketBeat.com, Cabaletta Bio  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $16.25.</p><p><b>Check Out Our Latest Stock Analysis on Cabaletta Bio</b></p><h2>Cabaletta Bio Company Profile</h2> (Get Free Report)<p>Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.  </p><p>The company's lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Cabaletta Bio</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FCQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cabaletta Bio Right Now?</h2><p>Before you consider Cabaletta Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabaletta Bio wasn't on the list.</p><p>While Cabaletta Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

IBBQ

<p>Cabaletta Bio (NASDAQ:CABA) is set to release its Q4 2025 earnings on March 12, with analysts expecting a loss of $0.4579 per share. The stock has seen a 5.5% increase, opening at $3.43, with a market cap of $330.17 million. Recent insider trading includes purchases by CEO Steven Nichtberger and insider Steve Gavel. Institutional investors have also increased their stakes, with T. Rowe Price and Adage Capital among the notable investors. Weiss Ratings has issued a "sell (d-)" rating, while the consensus rating remains a "Moderate Buy" with a price target of $16.25.</p>

Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday